Early Detection of Mild Cognitive Impairment (Mci) in an at-Home Setting

Abstract

Emerging digital tools have the potential to enable a new generation of qualitative and quantitative assessment of cognitive performance. Moreover, the ubiquity of consumer electronics, such as smartphones and tablets, can be harnessed to support large-scale self-assessed cognitive screening with benefit to healthcare systems and consumers. A wide variety of apps, wearables, and new digital technologies are either available or in development for the detection of mild cognitive impairment (MCI), a risk factor for dementia. Two categories of novel methodologies may be considered: passive technologies (which monitor a user’s behavior without active user input) and interactive assessments (which require active user input). Such examinations can be self-administered, supervised by a caregiver, or conducted by an informant at home or outside of a clinical setting. These direct-to-consumer tools have the potential to sidestep barriers associated with cognitive evaluation in primary care, thus improving access to cognitive assessments. Although direct-to-consumer cognitive assessment is associated with its own barriers, including test validation, user experience, and technological concerns, it is conceivable that these issues can be addressed so that a large-scale, self-assessed cognitive evaluation that would represent an initial cognitive screen may be feasible in the future.

Validity and Cultural Generalisability of a 5-Minute AI-Based, Computerised Cognitive Assessment in Mild Cognitive Impairment and Alzheimer's Dementia

“…In anticipation of disease-modifying treatments for MCI and AD ( 5 , 6 ), the importance of early diagnosis has become increasingly pressing ( 7 ). There is accumulating evidence that early detection provides cost savings for health care systems and is an achievable goal ( 8 , 9 ), and accurate patient selection for disease-modifying treatments is cost-effective and will improve clinical outcomes ( 5 ).…”

Validity and cultural generalisability of a 5-minute AI-based, computerised cognitive assessment in Mild Cognitive Impairment and Alzheimer’s Dementia

“…4 In anticipation of disease-modifying treatments for MCI and AD, 5,6 the importance of early diagnosis has become increasingly pressing. 7 There is accumulating evidence that early detection provides cost savings for health care systems and is an achievable goal, 8,9 and accurate patient selection for disease-modifying treatments is cost-effective and will improve clinical outcomes. 5 Timely identification and diagnosis is considered to be key to tackling dementia offering multiple benefits to patients, families and caregivers, healthcare providers, as well as society as a whole.…”

Validity of the Web-based, Self-directed, NeuroCognitive Performance Test in MCI

“…The advent of cloud-based online and smartphone cognitive tests has enhanced access to home-based and point of care memory evaluation (1)(2)(3). There has been a recent proliferation of such tests including several that have been cleared by regulatory agencies (4)(5)(6)(7)(8)(9)(10)(11)(12)(13).…”